NDAORALTABLET, ORALLY DISINTEGRATING
Approved
Jul 2007
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
6
Data completeness
4/8 — Partial
CHILDREN'S ALLEGRA ALLERGY (fexofenadine hydrochloride) by Sanofi. Approved for these symptoms due to hay fever, other upper respiratory allergies: runny nose sneezing itchy, water eyes itching of the nose and 1 more indications. First approved in 2007.
Drug data last refreshed 35m ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Children's Allegra Allergy is an orally disintegrating tablet formulation of fexofenadine hydrochloride, a second-generation H1-receptor antagonist approved by the FDA in 2007. It treats allergic rhinitis symptoms including runny nose, sneezing, itchy eyes, and throat itching due to hay fever and upper respiratory allergies. The drug works by blocking histamine receptors to reduce allergic response without significant CNS penetration.
LOE Approaching
The product is in late-stage lifecycle with moderate competitive pressure (30/100), signaling consolidation of existing teams and shift toward generic transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Worked on CHILDREN'S ALLEGRA ALLERGY at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.